Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

12548

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Sickle Cell Disease
Interventions: Mitapivat, Mitapivat-matching placebo; Drug · Other
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 28
States / cities: La Jolla, California • Los Angeles, California • Oakland, California + 20 more

Conditions: Breast Cancer
Interventions: GDC-4198, Giredestrant, Abemaciclib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Huntsville, Alabama • Tucson, Arizona • Duarte, California + 29 more

Conditions: Active Rheumatoid Arthritis
Interventions: ELV001 25 mg, ELV001 75 mg, ELV001 125 mg, Placebo; Drug
Lead sponsor: Elevara Medicines Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 22
States / cities: Gilbert, Arizona • Glendale, Arizona • Tucson, Arizona + 18 more

Conditions: HIV Infections
Interventions: ACCESS Intervention, Control Group; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Leptomeningeal Metastasis, Breast Cancer, Lung Cancer (NSCLC)
Interventions: Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI); Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: AZD6793, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 86
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more

Conditions: Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Interventions: Boric acid, Placebo; Drug · Other
Lead sponsor: pH-D Feminine Health LLC; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 26
States / cities: Mobile, Alabama • Little Rock, Arkansas • Huntington Park, California + 20 more

Conditions: Major Depression, Generalized Anxiety, Emotions
Interventions: Academic Performance Feedback; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 35 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Dravet Syndrome
Interventions: ETX101; Drug
Lead sponsor: Encoded Therapeutics; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more

Conditions: Hypertension
Interventions: Saline, QCZ484; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 63
States / cities: Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 58 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 30
States / cities: Lancaster, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Advanced Renal Cell Carcinoma (RCC)
Interventions: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 17
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more

Clinical trials in Miami, Florida

Filter and sort this location

Live official records

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

Neural Mechanisms of Real-world Emotions and Internalizing

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)